Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

Completed · Phase 2

Conditions studied: Uveitis

In brief

The purpose of this study is to assess the safety and efficacy of Adalimumab in uveitis.

Key facts

Study ID

NCT00525902

Run by

Oregon Health and Science University

People needed

31

Starts

2008-01-01

Expected to finish

2010-09-01

Last updated by the study team

2012-04-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with vision-threatening autoimmune uveitis.
• Failure to respond to prednisone and at least one other systemic immunosuppressive (such as methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, or chlorambucil), or intolerance to such medications due to side effects.

You may not qualify if…

• Serious concomitant illness that could interfere with the subject's participation in the trial.
• Previous or current use of cyclophosphamide.
• Unable or unwilling to undergo multiple injections.

Where it is running

• Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.